Spyre Therapeutics (SYRE) Stock: Buy, Sell, or Hold?
SYRE - Spyre Therapeutics, Inc. Common Stock
$93.19
3.26 (3.63%)
▲
5d:
+8.75%
30d:
+7.05%
90d:
+5.01%
BUY
HIGH Confidence
Analysis Updated: Oct 2, 2026 12:00 AM ET
Earnings: Nov 03, 2026
Get Alerted When SYRE Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: SYRE shows strong fundamentals and good volume confirmation. Solid entry point despite fair pricing.
✅ BUY SIGNAL: SYRE shows strong fundamentals and good volume confirmation. Solid entry point despite fair pricing.
In-depth Analysis How we analyze
Valuation Analysis: SYRE is currently trading at $93.19, which is considered fair relative to its 30-day fair value range of $85.65 to $95.78.
Technical Outlook: Technically, SYRE is in a uptrend. The price is approaching resistance at $95.27. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 3.6% recently.
Market Sentiment: SYRE scores 70/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $120.21 (+29.0%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, SYRE is in a uptrend. The price is approaching resistance at $95.27. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 3.6% recently.
Market Sentiment: SYRE scores 70/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $120.21 (+29.0%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$85.65 -
$95.78
Company Quality Score
56/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
92.1%
All Signals
- NEUTRAL: Price in fair range
- BULLISH: Strong technical setup (70/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+3.6%)
- BULLISH: Trading 29.0% below Wall St target ($120.21)
- BULLISH: Bottoming setup score 70/100 — corrected, stabilizing, and turning up
Trading Range Analysis
30-Day Trading Range
$85.65 -
$95.78
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$82.93
Resistance Level
$95.27
Current Trend
Uptrend
Technical data as of
Oct 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-26.47
Wall Street Target
$120.21
(+29.0%)
Earnings Growth (YoY)
-99.7%
Share & Embed Analysis
Last updated: October 02, 2026 5:26 PM ET
Data refreshes hourly during market hours. Next update: 6:26 PM
Data refreshes hourly during market hours. Next update: 6:26 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is SYRE showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
IONS
Ionis Pharmaceuticals Inc |
BUY
26 analysts |
$84 | 71 BUY |
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$75 | 60 BUY |
|
VKTX
Viking Therapeutics Inc |
STRONG BUY
19 analysts |
$95 | 57 HOLD |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$113 | 50 HOLD |
|
BEAM
Beam Therapeutics Inc |
STRONG BUY
17 analysts |
$52 | 66 BUY |
